Annexin Pharmaceuticals AB (OSTO:ANNX) Total Assets: kr19.98 Mil (As of Mar. 2026)


OSTO:ANNX Annexin Pharmaceuticals AB OSTO:ANNX
23 GF Score
Price kr13.00
! 1 Warning Sign
View Full Analysis

What is Annexin Pharmaceuticals AB Total Assets?

Annexin Pharmaceuticals AB OSTO:ANNX +4.00% 23 Total Assets is kr19.98 Mil as of Mar. 2026. GuruFocus rates OSTO:ANNX with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

Annexin Pharmaceuticals AB's Total Assets for the quarter that ended in Mar. 2026 was kr19.98 Mil.

During the past 12 months, Annexin Pharmaceuticals AB's average Total Assets Growth Rate was 2.30% per year. During the past 3 years, the average Total Assets Growth Rate was -20.80% per year. During the past 5 years, the average Total Assets Growth Rate was -14.10% per year. During the past 10 years, the average Total Assets Growth Rate was -9.30% per year.

During the past 11 years, Annexin Pharmaceuticals AB's highest 3-Year average Total Assets Growth Rate was 88.40%. The lowest was -40.70%. And the median was -14.75%.

Total Assets is connected with ROA %. Annexin Pharmaceuticals AB's annualized ROA % for the quarter that ended in Mar. 2026 was -167.81%. Total Assets is also linked to Revenue through Asset Turnover. Annexin Pharmaceuticals AB's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Annexin Pharmaceuticals AB  (OSTO:ANNX) Total Assets Explanation

Total Assets is connected with ROA %.

Annexin Pharmaceuticals AB's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-42.064/( (30.156+19.978)/ 2 )
=-42.064/25.067
=-167.81 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Annexin Pharmaceuticals AB's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (30.156+19.978)/ 2 )
=0/25.067
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Annexin Pharmaceuticals AB Total Assets Related Terms

Annexin Pharmaceuticals AB Total Assets Historical Data

* Premium members only.

The historical data trend for Annexin Pharmaceuticals AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annexin Pharmaceuticals AB Total Assets Chart

Annexin Pharmaceuticals AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.79 36.68 26.76 19.04 30.16

Annexin Pharmaceuticals AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.01 49.09 39.51 30.16 19.98
OSTO:ANNX
23GF Score
Annexin Pharmaceuticals AB OSTO:ANNX
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexin Pharmaceuticals AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Annexin Pharmaceuticals AB's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=24.932+5.224
=30.16

Annexin Pharmaceuticals AB's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=14.416+5.562
=19.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of kr19.98 Mil mean?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a Total Assets of kr19.98 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Annexin Pharmaceuticals AB and its competitors.
Is Annexin Pharmaceuticals AB's Total Assets too high?
Annexin Pharmaceuticals AB's current Total Assets is kr19.98 Mil. Overall, Annexin Pharmaceuticals AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Annexin Pharmaceuticals AB's Total Assets compare to VRTX and REGN?
Annexin Pharmaceuticals AB's Total Assets of kr19.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Annexin Pharmaceuticals AB and its competitors. Annexin Pharmaceuticals AB's current Total Assets is kr19.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexin Pharmaceuticals AB stock overvalued right now?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a current Total Assets of kr19.98 Mil. The current Total Assets is kr19.98 Mil. Annexin Pharmaceuticals AB's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Annexin Pharmaceuticals AB (OSTO:ANNX), the current Total Assets is kr19.98 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annexin Pharmaceuticals AB Business Description

Other Exchanges Q910:Germany
Address Kammakargatan 48, Stockholm, SWE, 111 60
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
23GF Score

Get the complete analysis for OSTO:ANNX

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr13.00
Price